# Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

Source: https://onco.cc/trials/nct06523049/  
OnCo record `nct06523049` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Vorolanib and Sintilimab in Renal cell carcinoma, run by Hao Zeng, not yet recruiting.

## Summary

Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy is a phase 2 interventional study registered as NCT06523049 by Hao Zeng, with 67 participants planned, started 2024-08 and due to reach its primary completion in 2026-07. Interventions recorded: Vorolanib Tablets, Sintilimab Injection. Conditions recorded: Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy.

Linked to the drug Vorolanib because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06523049
- Phase: 2
- Setting: A Prospective, Multicenter, Phase II Clinical Trial of Vorolanib in Combination With Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
- Sponsor: Hao Zeng
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT06523049: https://clinicaltrials.gov/study/NCT06523049

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Sintilimab](https://onco.cc/drugs/sintilimab/), [Vorolanib](https://onco.cc/drugs/vorolanib/)

---
JSON: https://onco.cc/api/v1/entities/nct06523049.json